Dengue Virus combined with autologous dendritic cells

PrimeVax Immuno-Oncology is at the forefront of developing innovative cancer therapies by harnessing the unique properties of the dengue virus. Their lead product, PV001-DV, is a live, attenuated strain of the dengue virus that has been extensively studied for over two decades, originally developed as a vaccine by the U.S. Army. This novel approach aims to utilize the dengue virus as an oncolytic virotherapy, specifically targeting late-stage cancers that have not responded to conventional treatments. The company has demonstrated that PV001-DV can elicit a robust anti-cancer immune response while maintaining a high safety profile, making it a promising candidate for clinical application. The technology is designed to induce both local and systemic immune responses, which are critical for overcoming immune evasion in cancer.

The therapeutic potential of PV001-DV is supported by clinical studies that have shown its ability to stimulate strong immune responses in both healthy volunteers and cancer patients. PrimeVax's research indicates that the dengue virus can achieve tumor killing through multiple mechanisms, including direct oncolytic effects and broad immunostimulatory actions. The company is currently focusing on melanoma as its initial target, with plans to expand into other solid tumors and explore combinations with existing immunotherapies. Through collaborations with esteemed partners, including the U.S. Army and various research institutions, PrimeVax is poised to advance its clinical pipeline and contribute significantly to the field of immuno-oncology.

United States

PrimeVax Immuno-Oncology, Inc. is developing the only one-time, one-week cancer treatment. We use a combination of the dengue fever virus and autologous dendritic cells to induce a strong immune response along with personalized tumor targeting.

PrimeVax Immuno-Oncology

Company Details